

How Do I FIND the Anastomosis??

Kerri Novak MD

University of Calgary, Alberta, Canada



international bowel
ULTRASOUND GROUP



Intestinal Ultrasound
Group of the United
States and Canada



FACULTY OF MEDICINE | UNIVERSITY OF CALGARY

Faculty Disclosures

Speaker: Janssen, Abbvie, Takeda, Pfizer

Advisory boards: Janssen, Abbvie, Takeda, Eli Lilly, Pfizer, Janssen, Ferring, Amgen, Fresenius Kabi, Celltrion, Merck, Bristol Myers Squibb

Research Support: Helmsley Trust, DOVA health, Janssen


Learning Objectives

1. Locate, identify the anastomotic constituents of the postoperative anastomosis (including the anatomic configuration).
2. Understand and interpret the findings at the the post-operative anastomosis, to exclude/ identify complications, determine and grade recurrent inflammation at key anastomotic components.



Monitoring post operative Crohn's disease – does it matter?

- Up to 90% of patients exhibit endoscopic recurrence (Ri1) at 12mo w most exhibiting activity at **3 years**.
 - Clinical recurrence occurs much later¹
- ~46% of CD patients require surgery within 10 yrs of Dx (range is 36-86% 37.7 % rate for kids^{2,3} & ~50% repeat surgery w/in 20 years⁴
 - Lower rate of dvlping small bowel disease post colectomy but 20-40%
- Evidence for surgery first line in limited TI disease (LIRIC trial) may argue for more surgery⁵





1. Hamilton AL et al. JCC 2022;16(12):1797
2. Yamao et al. Exp Review Gastro Hep 2015;9(1):55-66
3. Spinelli et al W J Gastro 2011;17(27):3213
4. Buisson et al. Aliment Pharmacol Ther, 2012. 35(6): p. 625–33
5. Stevens TW et al. Lancet Gastroenterol Hep 2020;5(10):900-907




Endoscopy: our gold standard

- Rutgeert's score developed in the 1990s – limited to disease proximal to the anastomotic inlet – designed for END to END anast (not side to side)

i0	i1	i2		i3	i4
		i2a	i2b		
					
No lesion in distal ileum	≤5 Aphthous lesions	Lesions confined to ileocolonic anastomosis	>5 Aphthous lesions with normal mucosa between the lesions	Diffuse aphthous ileitis with diffusely inflammed mucosa	Diffuse inflammation with already large ulcers and/or narrowing


CT & MR – useful?

- 11 studies, 589 patients (4CTE, 7MRE)
- **MRE** pooled sens & spec were 90% (95%CI 0.78-0.96) and 78% (95%CI 0.57-0.90) respectively
- **CTE** pooled sens & spec were 93% (95%CI 0.87-0.96) and 67% (95%CI 0.35-0.90) respectively
- Most sens & spec parameters: **wall thickening**, penetrating lesions¹
- **Colonic disease? *****



Biomarkers


- CRP and ESR insensitive for detecting POR¹
- FC levels are higher in those with endoscopic disease activity compared to those in remission with good correlation with the Rutgeert's score²
- ECCO guidelines recommend FC measure 3mo post op with endoscopy guided by the level³



1. Yamaomo et al. Exp Review Gastro Hep 2015;9(1):55-66
2. Boschetti et al. Official J of College of Gastro, ACG. 2015;10(6):865-872.
3. Dragoni et al. JCC 2023;17(9):1373-1386.

Success?

- Retrospective USA study, 901 post op CD patients, at least 1 yr after OR (2009-2019)¹
 - Biomarkers (FC, CRP), imaging & IC (Rutgeert's $\geq 2b$)
- 78% considered high risk (HR), 28% 2 or more surgeries
- 38.1% of HR had monitoring w IC within 1yr






IUS Accuracy

- **Pooled sensitivity of 0.89** [95% CI, 0.75-0.96] and **specificity of 0.76** [95% CI, 0.52-0.90]; using varying definitions of recurrence, sensitivity could be improved to 0.93 [95% CI, 0.80-0.98] and specificity to 0.85 [95% CI, 0.71-0.93]¹

Acc

- S
- P
- F
- O
- C
- S



ts,

CI

vere

FIGURE 3. Summary receiver operating characteristic plot presenting test performance of US in detecting postsurgical recurrence.

Rispo et al.
Inflamm Bowel
Dis 2018;24(5):977

Table 3. Diagnostic Accuracy of Noninvasive Parameters Alone or in Combination in Detecting Endoscopic Recurrence (95% CI): Per-patient Analysis


	Sensitivity, % (95% CI)	Specificity, % (95% CI)	Accuracy, % (95% CI)	PPV, % (95% CI)	NPV, % (95% CI)
BWT \geq 3 mm	77 (64–87)	65 (45–81)	73 (62–81)	81 (68–90)	59 (41–75)
FC \geq 50 mcg/g	83 (70–91)	64 (44–81)	76 (65–85)	81 (68–90)	67 (46–83)
Presence of lymph nodes	35 (23–48)	97 (83–100)	56 (45–66)	95 (77–100)	43 (32–56)
BWT \geq 3 mm and FC \geq 50 mcg/g	65 (51–78)	93 (76–99)	75 (64–84)	94 (81–99)	59 (43–74)
BWT $>$ 3 mm and FC $>$ 50 mcg/g and lymph nodes	33 (20–48)	100	66 (55–75)	100	59 (47–70)
BWT \geq 3 mm or FC \geq 50 mcg/g	93 (83–98)	34 (18–54)	74 (63–83)	74 (63–84)	71 (42–92)
BWT \geq 3 mm or FC \geq 50 mcg/g or lymph nodes	97 (88–100)	34 (18–54)	76 (66–85)	75 (64–84)	83 (52–98)

Principles


- Finding the anastomosis can be a treasure hunt – it doesn't need to be; nor should the disease distribution be a mystery. **MOST common operation in CD is an ILEOCECTOMY**
- REVIEW the operative report - caveat, no standards for operative reports currently exist
- REVIEW prior imaging

**R-hemi: anast will be HIGH
in the RUQ; ileocecectomy –
RLQ**






A. Side-to-side Isoperistaltic ileocolic anastomosis



Beslenghi et al. Archives of Surgery 202
Debove et al. J of Visceral Surg 2012;14




***Side-to-side antiperistaltic
ileocolic anastomosis***



***Side-to-side isoperistaltic
ileocolic anastomosis***


Areas of interest for endoscopic follow-up are reported in different colors.

	Ileal body		Neo-terminal ileum
	Anastomotic line		Ileal inlet
	Colonic blind loop		Ileal blind loop




C. *End-to-end ileocolic anastomosis*

A




End-to-end ileocolic anastomosis




Kono-S ileocolic anastomosis

Areas of interest for endoscopic follow-up are reported in different colors.






End-to-side ileocolic anastomosis









Side-to-end ileocolic anastomosis B

Areas of interest for endoscopic follow-up are reported in different colors.

- | | | | |
|---|--------------------|---|--------------------|
|  | Ileal body |  | Neo-terminal ileum |
|  | Anastomotic line |  | Ileal inlet |
|  | Colonic blind loop |  | Ileal blind loop |






Expert Consensus

- Modified RAND-University of California Los Angeles appropriateness method implemented using an international panel of 16 experts (rads, GI, surgeons)¹
- **Detail** is important so use a high freq transducer where possible
- **No prep**; however, if pre-test probably of stricture HIGH can consider oral prep/ neg contrast (SICUS/ 500c Colyte).
- Documenting **whether or not the anastomosis was seen** is important - in addition to location, anatomic type

Expert Consensus

- ALL anatomic constituents of the "anastomosis" that should be systematically evaluated include: the **neoterminal ileum (NTI)**, neoterminal ileal **inlet**, colonic and ileal blind side of the anastomosis (the colonic segment immediately distal to the anastomosis).
- The NTI BWT should be measured 1 cm from the inlet to avoid estimations confounded by the surgical staple line.
- Use of all standard parameters important (there is no currently validated postoperative activity score), including evaluation of complications (strictures using CONSTRICT guidelines).



Neoterminal ileum
BWT

staples

Colon
Normal BWT

Narrowed inlet

Neo-terminal ileum

Bowel wall thickness measure, 1cm from the inlet

Anastomotic Inlet

Colon - BWT

Staples


Ileocolic anastomosis

Stool/
air

Muscularis propria ▲

Submucosa ◆

Mucosa ●



[2D]
Pen1
Gn 60
DR 104
FA 5
P 90%



TI AX

[2D]
Gen
Gn 47
DR 118
FA 2
P 80%

S



TI



[2D]

Gen
Gn 47
DR 118
FA 2
P 80%

[C]

Pen
Gn 50
PRF 0.59kHz
P 90%

S



0
1
2
3
4
5
6
7

TI

Case. MP

MP is a 28yo man with structuring ileal CD (Montreal classification A2 (diagnosed 18yrs), L1 (limited to the TI) and B3 (structuring in the absence of perianal disease

Non-smoker

Started on IFX monotherapy and treated with escalating doses to target optimal drug level.

BOWEL 1

C9-2

56Hz

R1

2D

43%

Dyn R 55

P Low

HRes


TISO.2

MI 1.3

M4



*** bpm



Case 2. MP



Post-operatively we restarted IFX

Felt extremely well, is vigilant with his eating (eating "clean"), fit, active and as no symptoms (HBI = 0)

Follows up to discuss stopping IFX given recurrent viral infections


Blood work:


Ferritin is 18, Hb 142 MCV 85, plt 287, WBC 6.1


Cr, liver enzymes normal



Fecal cal: pending

CA3-10A / Abdomen / FPS34 / MI1.1 / TIs0.3 / 2022-08-24 09:30:31 AM
2D G44/DR35/FA10/P90/Frq Res./7.0cm











Asc colon

CA3-10A / Abdomen / FPS11 / MI1.3 / TIs0.5 / 2022-08-24 09:31:46 AM
2D G44/DR35/FA10/P90/Frq Res /7.0cm
C G72/0.37kHz/F1/FA6












[2D]
Pen1
Gn 60
DR 104
FA 5
P 90%

S




TI AX

[2D]
Pen1
Gn 60
DR 104
FA 5
P 90%




TIAX



SIDE TO END anastomosis

S



Wall thickness NTI

Neoterminal ileum (NTI)

Inlet - side to end anastomosis

Air shadowing

[2D]

Pen1

Gn 60

DR 104

FA 5

P 90%

[S-Flow]

Pen

Gn 55

PRF 0.71kHz

P 90%

S



6.0

0

-

-6.0

cm/s

1

2


3

4

5

6


TI AX







Personalized Pre-operative RISK STRATIFICATION





Thank you